Advertisement

Clinical Pharmacokinetics

, Volume 6, Issue 4, pp 245–258 | Cite as

Clinical Pharmacokinetics of Indomethacin

  • Lars Helleberg
Article

Abstract

Indomethacin (l-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid) is an anti-inflammatory antipyretic drug commonly used for symptomatic relief of pain and stiffness in rheumatic diseases.

Following oral administration the absorption of the drug is rapid and complete, but with important inter- and intraindividual variations. In general, peak plasma concentrations of 2 to 3μg/ml are achieved within 1 to 2 hours, but concomitant ingestion of food reduces and delays the peak concentrations without reducing the amount absorbed. Rectal administration is associated with earlier but lower peak plasma concentrations, incomplete absorption from suppositories, and offers no clinical advantages when compared with equivalent oral dosage. In plasma at least 90% of indomethacin is bound to albumin at therapeutic plasma concentrations. Indomethacin is distributed into the synovial fluid, is excreted in human breast milk and crosses the placenta in significant amounts. It is metabolised to O-desmethylindomethacin, N-deschlorobenzoylindomethacin and O-desmethyl-N-deschlorobenzoylindomethacin, which are devoid of anti-inflammatory activity and are present in significant amounts in the plasma.

About 60% of an oral dose is excreted in the urine predominantly in glucuronidated form, while about 40% is excreted in the faeces after biliary secretion. A large amount of the dose undergoes biliary recycling. The biotransformation is independent of the route of administration. A 2-compartment open model with correction for biliary recycling can be used to describe the disposition of indomethacin. The drug has a biological half-life of about 5 to 10 hours and a plasma clearance of 1 to 2.5ml/kg/min. In premature infants the half-life of indomethacin is inversely correlated with gestational age and is significantly prolonged as compared with adults. Renal failure does not affect the serum concentrations of indomethacin. Probenecid results in increased plasma concentrations of indomethacin with enhanced pain relief without increasing the incidence of side effects. There seem to be no significant pharmacokinetic interactions between indomethacin and aspirin or warfarin.

To date it has not been possible to identify a relationship between the clinical effects and plasma concentration of indomethacin.

Keywords

Indomethacin Clinical Pharmacology Human Serum Albumin Patent Ductus Arteriosus Peak Plasma Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alpert, B.S.; Lewins, M.J.; Rowland, D.W.; et al.: Plasma indomethacin levels in preterm newborn infants with symptomatic patient ductus arteriosus — clinical and echocardiographic assessments of response. Journal of Pediatrics 9: 578 (1979).Google Scholar
  2. Alván, G.; Orme, M.; Bertillson, L.; Ekstrand, R. and Palmer, L.: Pharmacokinetics of indomethacin. Clinical Pharmacology and Therapeutics 18: 364–373 (1975).PubMedGoogle Scholar
  3. Anderson, D.R.; Phernetton, T.M. and Rankin, J.H.G.: The measurement of placental drug clearance in near-term sheep: indomethacin. Journal of Pharmacology and Experimental Therapeutics 213: 100 (1980).PubMedGoogle Scholar
  4. Arabin, A.: Three alkylation methods for the determination of indomethacin in plasma by electron capture gas liquid chromatography. Journal of Chromatography 144: 85–92 (1977).CrossRefGoogle Scholar
  5. Arnold, E. and Brynger, H.: Serum koncentrationsmätningar efter administration av indomethacin kapslar och suppositorier. Opuscula Medica 15: 333–336 (1970).Google Scholar
  6. Baber, N.; Halliday, L.D.C.; Van Den Heuvel, W.J.A.; Walker, R.W.; Sibeon, R.; Keenan, J.P.; Littler, T. and Orme, M.: Indomethacin in rheumatoid arthritis: Clinical effects, pharmacokinetics and platelet studies in responders and nonresponders. Annals of the Rheumatic Diseases 38: 128–137 (1979).PubMedCrossRefGoogle Scholar
  7. Bhat, R.; Vidyasagar, D.; Fisher, E. et al.: Pharmacokinetics of oral and intravenous indomethacin in preterm infants. Developmental Pharmacology and Therapeutics 1: 101 (1980).PubMedGoogle Scholar
  8. Bhat, R.; Vidyasagar, D.; Vadapalli, M. et al.: Disposition of indomethacin in preterm infants. Journal of Pediatrics 95: 313 (1979).PubMedCrossRefGoogle Scholar
  9. Bianchetti, G.; Monin, P.; Marchai, F. et al.: Pharmacokinetics of indomethacin in the premature infant. Developmental Pharmacology and Therapeutics 1: 111 (1980).PubMedGoogle Scholar
  10. Brooks, P.M.; Bell, M.A.; Lee, P.; Rooney, P.J. and Dick, W.C.: The effect of frusemide on indomethacin plasma levels. British Journal of Clinical Pharmacology 1: 485–489 (1974a).PubMedCrossRefGoogle Scholar
  11. Brooks, P.M.; Bell, M.A.; Sterrock, R.D.; Famaey, J.P. and Dick, W.C.: The clinical significance of the indomethacin-probenecid interaction. British Journal of Clinical Pharmacology 1: 287–290 (1974b).PubMedCrossRefGoogle Scholar
  12. Brooks, P.M.; Walker, J.J.; Bell, M.A.; Buchannan, W.W. and Rhymer, A.R.: Indomethacin-aspirin interaction: A clinical appraisal. British Medical Journal 3: 69–71 (1975).PubMedCrossRefGoogle Scholar
  13. Caruso, I.: Verteilung von Indomethazin in Blut und Synovialflussigheit chronischer Polyarthritiker. Arzneimittel-Forschung 21: 1824–1826 (1971).PubMedGoogle Scholar
  14. Champion, G.D.; Paulus, H.E.; Mongan, E.; Okun, R.; Pearson, C.M. and Sarkissian, E.: The effect of aspirin on serum indomethacin. Clinical Pharmacology and Therapeutics 13: 239–244 (1972).PubMedGoogle Scholar
  15. Dick, W.C.: Drug treatment of rheumatoid arthritis; in Scott (Ed) Copeman’s Textbook of the Rheumatic Diseases 5th ed., pp.404–446 (Churchill Livingstone, New York 1978).Google Scholar
  16. Duggan, D.E.; Hogans, A.F.; Kwan, K.C. and McMahon, F.G.: The metabolism of indomethacin in man. Journal of Pharmacology and Experimental Therapeutics 181: 563–575 (1972).PubMedGoogle Scholar
  17. Duggan, D.E.; Hooke, K.F.; Noll, R.M. and Kwan, K.C.: Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochemical Pharmacology 25: 1749–1754 (1975).CrossRefGoogle Scholar
  18. Eeg-Olofsson, O.; Malmros, I.; Elwin, C.E. and Steen, B.: Convulsions in a breast-fed infant after maternal indomethacin. Lancet 2: 215 (1978).PubMedCrossRefGoogle Scholar
  19. Emori, H.W.; Champion, G.D.; Bluestone, R. and Paulus, H.E.: Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid. Annals of the Rheumatic Diseases 32: 433–435 (1973).PubMedCrossRefGoogle Scholar
  20. Emori, H.W.; Paulus, H.; Bluestone, R.; Champion, G.D. and Pearson, C.: Indomethacin serum concentrations in man. Effects of dosage, food and antacid. Annals of the Rheumatic Diseases 35: 333–338 (1976).PubMedCrossRefGoogle Scholar
  21. Evans, M.A.; Bhat. R.; Vidyasagar, D. et al.: Gestational age and indomethacin elimination in the neonate. Clinical Pharmacology and Therapeutics 26: 746 (1979).PubMedGoogle Scholar
  22. Ferreira, S.H.; Moncada, S. and Vane, J.R.: Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature New Biology 231: 237–239 (1971).PubMedCrossRefGoogle Scholar
  23. Ferry, D.C.; Ferry, D.M.; Moller, P.W. and McQueen, E.G.: Indomethacin estimation in plasma and serum by electron capture gas chromatography. Journal of Chromatography 89: 110–112 (1974).PubMedCrossRefGoogle Scholar
  24. Friedman, Z.; Whitman, V.; Maiseis, M.J.; Berman, W.; Marks, K.H. and Vesell, E.S.: Indomethacin disposition and indomethacin induced platelet dysfunction in premature infants. Journal of Clinical Pharmacology 13: 272–279 (1978).Google Scholar
  25. Garnham, J.C.; Kaspi, T.; Kaye, C.M. and Oh, V.M.S.: The different effects of sodium bicarbonate and aluminium hydroxide on the absorption of indomethacin in man. Postgraduate Medical Journal 53: 126–129 (1977).PubMedCrossRefGoogle Scholar
  26. Garnham, J.C.; Raymond, K.; Shotton, E. and Turner, P.: The effect of buffered aspirin on plasma indomethacin. European Journal of Clinical Pharmacology 8: 107–113 (1975).PubMedCrossRefGoogle Scholar
  27. Hawkins, D.; Pinckard, E.N.; Crawford, I.P. and Farr, R.S.: Structural changes in human serum albumin induced by ingestion of acetylsalicylic acid. Journal of Clinical Investigation 48: 536–542 (1969).PubMedCrossRefGoogle Scholar
  28. Helleberg, L.: Determination of indomethacin in serum and urine by electron capture gas-liquid chromatography. Journal of Chromatography 117: 167–173 (1976).PubMedCrossRefGoogle Scholar
  29. Helleberg, L.; Gylding-Sabroe, J. and Sylvest, J.: The effect of aspirin on the physiological disposition of indomethacin in man. Scandinavian Journal of Rheumatology 6: 71 (1977).Google Scholar
  30. Holt, L.P.J. and Hawkins, C.F.: Indomethacin: Studies of absorption and the use of indomethacin suppositories. British Medical Journal 1: 1354–1356 (1965).PubMedCrossRefGoogle Scholar
  31. Hucker, H.B., Zacchei, A.C.; Cox, S.V.; Brodie, D.A. and Cantwell, N.H.R.: Studies on the absorption, distribution and excretion of indomethacin in various species. Journal of Pharmacology and Experimental Therapeutics 153: 237–249 (1966).Google Scholar
  32. Hultmark, D.; Borg, K.O.; Elofsson, R. and Palmer, L.: Interaction between salicylic acid and indomethacin in binding to human serum albumin. Acta Pharmaceutica Suecica 12: 259–276 (1975).PubMedGoogle Scholar
  33. Huskisson, E.C.; Taylor, R.T.; Burston, D.; Chuter, P.J. and Hart, F.D.: Evening indomethacin in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases 29: 393–396 (1970).PubMedCrossRefGoogle Scholar
  34. Hvidberg, E.; Lausen, H.H. and Jansen, J.A.: Indomethacin: Plasma concentrations and protein binding in man. European Journal of Clinical Pharmacology 4: 119–124 (1972).PubMedCrossRefGoogle Scholar
  35. Jensen, K.M.: Determination of indomethacin in serum by an extractive alkylation technique and gas-liquid chromatography. Journal of Chromatography 153: 195–202 (1978).PubMedCrossRefGoogle Scholar
  36. Jacobson, J.; Cavalli-Bjorkman, K.; Lundström, V.; Nilsson, B. and Norbeck, M.: Prostaglandin synthctasc inhibitors and dysmenorrhea. A survey and personal clinical experience. Acta Obstetrica et Gynecologica Scandinavica 87 (Suppl.): 73–79 (1979).CrossRefGoogle Scholar
  37. Jeremy, R. and Towson, J.: Interaction of aspirin and indomethacin in the treatment of rheumatoid arthritis. Medical Journal of Australia 2: 127–129 (1970).PubMedGoogle Scholar
  38. Kaldestad, E.; Hansen, T. and Brath, H.K.: Interaction of indomethacin and acetylsalicylic acid as shown by the serum concentrations of indomethacin and salicylate. European Journal of Clinical Pharmacology 9: 199–207 (1975).PubMedCrossRefGoogle Scholar
  39. Kunze, M.; Stein, G.; Kunze, E. and Traeger, A.: Zur Pharmakokinetik von Indomethazin in Abhaengigkeit von Lebensalter, bei Patienten mit Gallenwegsverschluss, Nierenfunktionseinschrankung und Unvertraglichkeitserscheinungen. Deutsche Gesundheitswesen 29: 351–353 (1974).Google Scholar
  40. Kwan, K.C.; Breault, G.O.; Davis, R.L. et al.: Effects of concomitant aspirin administration on the pharmacokinetics of indomethacin in man. Journal of Pharmacokinetics and Biopharmaceutics 6: 451 (1978).PubMedGoogle Scholar
  41. Kwan, K.C.; Breault, C.O.; Umbenhauer, E.R.; McMahon, F.G. and Duggan, D.E.: Kinetics of indomethacin absorption, elimination and enterohepatic circulation in man. Journal of Pharmacokinetics and Biopharmaceutics 4: 255–280 (1975).Google Scholar
  42. Lindquist, B.; Jensen, K.M.; Johansson, H. and Hansen, T.: Effect of concurrent administration of aspirin and indomethacin on serum concentrations. Clinical Pharmacology and Therapeutics 15: 247–252 (1974).PubMedGoogle Scholar
  43. Lockie, L.M.: Phenylbutazone, indomethacin and chloroquines in therapy of rheumatoid arthritis; in Hollander and McCarty (Eds) Arthritis and Allied Conditions, pp.438–494 (Lea and Febiger, Philadelphia 1972).Google Scholar
  44. Mason, R.W. and McQueen, E.G.: Protein binding of indomethacin: Binding of indomethacin to human plasma albumin and its displacement from binding by ibuprofen, phenylbutazone and salicylate, in vitro. Pharmacology 12: 12–19 (1974).PubMedCrossRefGoogle Scholar
  45. McArthur, J.N.; Dawkins, P.D. and Smith, M.J.H.: The binding of indomethacin, salicylate and phenobarbitone to human whole blood in vitro. Journal of Pharmaceutical Pharmacology 23: 32–36 (1971).CrossRefGoogle Scholar
  46. Merritt, T.A.; DiSessa, T.G.; Feldman, B.H.; Kirkpatrick, S.E.; Gluck, L. and Friedman, W.F.: Closure of the patent ductus arteriosus with ligation and indomethacin: A consecutive experience. Journal of Pediatrics 93: 639–646 (1978).PubMedCrossRefGoogle Scholar
  47. Nestrud, R.M.; Hill, D.E.; Arrington, R.W. et al.: Indomethacin treatment in patent ductus arteriosus. A double-blind study utilizing indomethacin plasma levels. Developmental Pharmacology and Therapeutics 1: 125 (1980).PubMedGoogle Scholar
  48. Norcross, B.M.: Treatment of connective tissue diseases with a new non-steroidal compound. Arthritis and Rheumatism 6: 290 (1963).Google Scholar
  49. O’Brien, W.M.: Indomethacin: A survey of clinical trials. Clinical Pharmacology and Therapeutics 9: 94–107 (1967).Google Scholar
  50. Palmér, L.; Bertilsson, L.; Alván, G.; Orme, M.; Sjöqvist, F. and Holmstedt, B.: Indomethacin: Quantitative determination in plasma by mass fragmentography including pilot pharmacokinetics in man; in Robinson and Vane (Eds) Prostaglandin Synthetase Inhibitors, pp.91–97 (Raven Press, New York 1974).Google Scholar
  51. Parks, B.R.; Jordan, R.L.; Rawson, J.E. et al.: Indomethacin: studies of absorption and placental transfer. American Journal of Obstetrics and Gynecology 129: 464 (1977).PubMedGoogle Scholar
  52. Plazonnet, B. and Van Den Heuvel, W.J.A.: Preparation, gas chromatography and mass spectrometry of methyl and trimethylsilyl esters of indomethacin. Journal of Chromatography 142: 587–596 (1977).PubMedCrossRefGoogle Scholar
  53. Rane, A.; Oelz, O.; Frolich, J.E. et al.: Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man. Clinical Pharmacology and Therapeutics 23: 658 (1978).PubMedGoogle Scholar
  54. Reinicke, C.; Hippius, N.; Berles, R. et al.: Studies on pharmacokinetic interactions of anti-inflammatory drugs in man. Effects of acetyl-salicylic acid, aluminium hydroxide gel, rimazolium methylsulphate (Probon) and food on indomethacin serum concentrations. International Symposium, Taormina, Nov. 1979. Tissue Reactions 1: 173 (1979).Google Scholar
  55. Rothermich, N.O.: Indomethacin: A new pharmacologic approach to the management of rheumatoid disease. Arthritis and Rheumatism 6: 295 (1963).CrossRefGoogle Scholar
  56. Rothermich, N.O.: An extended study of indomethacin. 1. Clinical pharmacology. Journal of the American Medical Association 195: 123–128 (1966).Google Scholar
  57. Rothermich, N.O.: The fate of rectally administered radioactive indomethacin in human subjects: A preliminary report. Clinical Pharmacology and Therapeutics 12: 300–301 (1971).Google Scholar
  58. Rubin, A.; Rodda, B.E.; Warrick, P.; Gruber, C.M. and Ridolfo, A.S.: Interactions of aspirin with nonsteroidal antiinflammatory drugs in man. Arthritis and Rheumatism 16: 635–645 (1973).PubMedCrossRefGoogle Scholar
  59. Seyberth, H.W., Segre, G.V.; Morgan, J.L.; Sweetman, B.J.; Potts, J.T. and Oates, J.A.: Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. New England Journal of Medicine 293: 1278–1283 (1975).PubMedCrossRefGoogle Scholar
  60. Sharpe, G.L.; Thalme, B. and Larsson, K.S.: Studies on closure of the ductus arteriosus. XI. Ductal closure in utero by a prostaglandin synthetase inhibitor. Prostaglandins 8: 363–368 (1974).PubMedCrossRefGoogle Scholar
  61. Shen, T.Y.: Synthesis and biological activity of some indomethacin analogs; in Garattini and Dukes (Eds) International Symposium of Non-Steroidal Anti-Inflammatory Drugs, pp.13–20 (International Congress Series No. 82, Amsterdam 1965).Google Scholar
  62. Shen, T.Y.; Windholz, T.B.; Rosegoy, A.; Witzel, B.E.; Wilson, A.N.; Willett, J.D.; Holtz, W.J.; Ellis, R.L.; Mattzuk, A.R.; Lucas, S.; Stammer, C.H.; Holly, F.W.; Sarett, L.H.; Risley, E.A.; Nuss, G.W. and Winter, C.A.: Non-steroidal anti-inflammatory agents. Journal of the American Chemical Society 85: 488–489 (1963).CrossRefGoogle Scholar
  63. Sibeon, R.G.; Baty, J.D.; Baber, N.; Chan, K. and Orme, M.: Quantitative gas-liquid Chromatographic method for the determination of indomethacin in biological fluids. Journal of Chromatography 153: 189–194 (1978).PubMedCrossRefGoogle Scholar
  64. Sjoqvist, F.; Borgä, O. and Orme, M.L’E.: Fundamentals of clinical pharmacology: protein binding of drugs; in Avery (Ed) Drug Treatment, 2nd ed, pp.16–21 (ADIS Press, New York and Sydney; Churchill Livingstone, Edinburgh 1980).Google Scholar
  65. Skeith, M.D.; Simkin, P.A. and Healey, L.A.: The renal excretion of indomethacin and its inhibition by probenecid. Clinical Pharmacology and Therapeutics 9: 89–93 (1968).PubMedGoogle Scholar
  66. Skellern, G.G. and Salole, E.G.: A high-speed liquid Chromatographic analysis of indomethacin in plasma. Journal of Chromatography 114: 483–485 (1975).PubMedCrossRefGoogle Scholar
  67. Sylvälahti, E.K.G.: The effect of indomethacin on serum growth hormone, immunoreactive insulin and blood glucose levels of young adult males. International Journal of Clinical Pharmacology 10: 111–116 (1974).Google Scholar
  68. Stein, G.; Kunze, M.; Zaumseil, J. et al.: Pharmacokinetics of indomethazine and metabolites of indomethazine continuously applied in patients with healthy and damaged kidneys. International Journal of Clinical Pharmacology and Biopharmacy 15: 470 (1977).PubMedGoogle Scholar
  69. Takyi, B.E.: Excretion of drugs in human milk. Journal of Hospital Pharmacy 28: 317–325 (1970).Google Scholar
  70. Tillement, J.P.T.; Lhoste, F. and Giudicelli, J.F.: Diseases and drug protein binding. Clinical Pharmacokinetics 3: 144–154 (1978).PubMedCrossRefGoogle Scholar
  71. Traeger, A.; Stein, G.; Kuntze, M. and Zaumseil, J.: Zur pharmakokinetik von Indomethazin bei nierengeschädigten patienten. International Journal of Clinical Pharmacology 6: 237–242 (1972).Google Scholar
  72. Turakka, H. and Airaksinen, M.M.: Biopharmaceutical assessment of phenylbutazone and indomethacin preparations. Annals of Clinical Research 6 (Suppl. 11): 34–41 (1974).PubMedGoogle Scholar
  73. Wallusch, W.W.; Nowak, H.; Leopold, G. et al.: Comparative bioavailability: Influence of various diets on the bioavailability of indomethacin. International Journal of Clinical Pharmacology and Biopharmacy 16: 40 (1978).PubMedGoogle Scholar
  74. Van Arman, C.G.; Nuss, G.W. and Risley, E.A.: Interactions of aspirin, indomethacin and other drugs in adjuvant-induced arthritis in the rat. Journal of Pharmacology and Experimental Therapeutics 187: 400–414 (1973).PubMedGoogle Scholar
  75. Vane, J.R.: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biology 231: 232–235 (1971).PubMedGoogle Scholar
  76. Vert, P.; Bianchetti, G.; Marchal, F. et al.: Effectiveness and pharmacokinetics of indomethacin in premature newborns with patient ductus arteriosus. European Journal of Clinical Pharmacology 18: 83 (1980).PubMedCrossRefGoogle Scholar
  77. Vesell, E.S.; Passananti, G.T. and Johnson, A.O.: Failure of indomethacin and warfarin to interact in normal human volunteers. Journal of Clinical Pharmacology 15: 486–495 (1975).PubMedGoogle Scholar
  78. Yesair, D.W. and Coutinho, C.B.: Method for extraction and separation of drugs and metabolites from biological tissue. Biochemical Pharmacology 19: 1569–1578 (1970).PubMedCrossRefGoogle Scholar
  79. Zuckerman, H.; Reiss, U. and Rubinstein, I.: Inhibition of human premature labor by indomethacin. Journal of Obstetrics and Gynecology 44: 787–792 (1974).Google Scholar

Copyright information

© ADIS Press Australasia Pty Ltd. 1981

Authors and Affiliations

  • Lars Helleberg
    • 1
  1. 1.Department of Physical Medicine T2002Rigshospitalet, University HospitalCopenhagenDenmark

Personalised recommendations